Jeffrey Holford
Stock Analyst at Keybanc
(2.83)
# 1,617
Out of 4,828 analysts
125
Total ratings
70.83%
Success rate
10.94%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Holford
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PH Parker-Hannifin | Maintains: Overweight | $775 → $790 | $647.59 | +21.99% | 1 | Jan 31, 2025 | |
| AZN AstraZeneca | Assumes: Hold | $42 | $67.57 | -37.84% | 3 | Dec 11, 2018 | |
| MRK Merck & Co. | Upgrades: Hold | n/a | $75.97 | - | 30 | Oct 31, 2017 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Hold | n/a | $46.45 | - | 27 | Oct 16, 2017 | |
| JNJ Johnson & Johnson | Upgrades: Buy | n/a | $154.22 | - | 28 | Oct 11, 2017 | |
| ABBV AbbVie | Maintains: Buy | $94 → $107 | $184.60 | -42.04% | 14 | Sep 15, 2017 | |
| LLY Eli Lilly and Company | Maintains: Buy | $89 → $96 | $734.57 | -86.93% | 22 | Sep 15, 2017 |
Parker-Hannifin
Jan 31, 2025
Maintains: Overweight
Price Target: $775 → $790
Current: $647.59
Upside: +21.99%
AstraZeneca
Dec 11, 2018
Assumes: Hold
Price Target: $42
Current: $67.57
Upside: -37.84%
Merck & Co.
Oct 31, 2017
Upgrades: Hold
Price Target: n/a
Current: $75.97
Upside: -
Bristol-Myers Squibb Company
Oct 16, 2017
Downgrades: Hold
Price Target: n/a
Current: $46.45
Upside: -
Johnson & Johnson
Oct 11, 2017
Upgrades: Buy
Price Target: n/a
Current: $154.22
Upside: -
AbbVie
Sep 15, 2017
Maintains: Buy
Price Target: $94 → $107
Current: $184.60
Upside: -42.04%
Eli Lilly and Company
Sep 15, 2017
Maintains: Buy
Price Target: $89 → $96
Current: $734.57
Upside: -86.93%